Premium
Transdermal scopolamine in the prevention of motion sickness at sea
Author(s) -
Price N M,
Schmitt L G,
McGuire J,
Shaw J E,
Trobough G
Publication year - 1981
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1981.57
Subject(s) - motion sickness , transdermal , scopolamine , placebo , medicine , anesthesia , pharmacology , psychiatry , alternative medicine , pathology
Studies were conducted to evaluate the efficacy of scopolamine, absorbed through intact skin, in preventing motion sickness at sea. Efficacy of transdermal scopolamine was compared with oral dimenhydrinate and placebo. Transdermal applications were made 4 to 16 hr before exposure to motion. Dimenhydrinate or placebo was given 1.5 hr before motion and again 2.5 hr after motion began. Comparison with placebo indicated that transdermal scopolamine provided protection against motion sickness at a significance level of p = 0.0001 and oral diphenhydrinate at a level of p = 0.05. Dry mouth, drowsiness, and blurred vision associated with transdermal scopolamine therapy were minimal. Clinical Pharmacology and Therapeutics (1981) 29, 414–419; doi: 10.1038/clpt.1981.57